DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20205318

Study of effect of diabetes mellitus on classical risk factors for coronary artery disease

Suchitra Garhwal, Anil Kumar Poonia, Veeha Agarwal

Abstract


Background: Diabetes mellitus (DM) is increasingly prevalent in general population and is associated with increased risk for coronary artery disease (CAD). DM both directly and indirectly increases risk of CAD. Quantum of DM associated increase in classical risk factor for CAD is not exactly described. In present study, association of traditional risk for CAD and DM was analyzed.

Methods: Total 150 patients with CAD were enrolled and divided into two group: group 1 with DM (84 patients) and group 2 without DM (66 patients). These two were compared and analyzed for classical risk factors for DM.

Results: CAD with DM group had higher prevalence for traditional risk for CAD than CAD alone group: for Hypertension relative prevalence was 67.8 and 36.3% respectively (p<0.05); for Obesity it was 79.7 and 40.9% respectively (p<0.05) and for Dyslipidemia relative prevalence was 75 and 37.8% respectively (p<0.05).

Conclusions: DM is major risk for CAD and it is also associated with increased prevalence for hypertension, obesity and dyslipidemia in affected population.


Keywords


DM, CAD, Hypertension, Obesity, Dyslipidemia

Full Text:

PDF

References


International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation. 2015.

Abraham TM, Pencina KM, Pencina MJ, Fox CS. Trends in diabetes incidence: the Framingham heart study. Diab Care. 2015;38:482-7.

International Diabetes Federation. Diabetes and cardiovascular disease. Brussels: International Diabetes Federation. 2016:1-144.

Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.

Prevalence of small vessel and large vessel disease in diabetic patients from 14 centers. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes Drafting Group. Diabetologia. 1985;28:615-40.

Ahmed I, Goldstein BJ. Cardiovascular risk in the spectrum of type 2 diabetes mellitus. Mt Sinai J Med. 2006;73:759-68.

Devaraj S, Jialal I. Oxidized low-density lipoprotein and atherosclerosis. Int J Clin Lab Res. 1996;26:178-84.

Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 26(5):1553-79.

Siqueira AFA, De Almeida-Pititto B, Ferreira SRG. Cardiovascular disease in diabetes mellitus: classical and non-classical risk factors. Arq Bras Endocrinol Metabol. 2007;51:257-67.

Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R et al. American Heart Association, American Diabetes Association: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162-72.

Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91.

Reddy KS. Epidemiology of vascular disease and risk factor in India. Metabolic syndrome proceeding of the VIIth Annual Ranbaxy science foundation symposium. 2000.

Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891-7.

Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345-61.

Miller M, Stone NJ, Ballantyne C, Bittner V. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292-333.

Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol. 2008;102:5L-9.

Nilsson PM, Cederholm J, Zethelius BR. Trends in blood pressure control in patients with type 2 diabetes: data from the Swedish National Diabetes Register (NDR). Blood Press. 2011;20:348-54.

Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K. Mechanisms of hypertension in the cardiometabolic syndrome. J Hypertens. 2009;27:441-51.

Mogensen CE. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl. 2003;21:S25-30.

Sobel BE. Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med. 2007;120:S3-11.

Sobel BE. Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and opportunities. Am J Cardiol. 2006;97:53G-8.

Eckel RH. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc Nutr Soc. 2007;66:82-95.

Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875-80.

Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-7.

Bittencourt C, Piveta VM. Association of classical risk factors and coronary artery disease in type 2 diabetic patients submitted to coronary angiography. Diabetol Metabolic Synd. 2014;6:46.

Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength. World J Diabetes. 2014;5(4):444-70.